Cellectis Stock (NASDAQ: CLLS) stock price, news, charts, stock research, profile.
Open | $3.010 |
Close | $3.240 |
Volume / Avg. | 127.926K / 51.616K |
Day Range | 3.010 - 3.320 |
52 Wk Range | 0.963 - 3.774 |
Market Cap | $233.129M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 68 |
Short Interest | 1.49% |
Days to Cover | 19.05 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Cellectis (NASDAQ: CLLS) through any online brokerage.
Other companies in Cellectis’s space includes: Renovaro (NASDAQ:RENB), Innate Pharma (NASDAQ:IPHA), Adverum Biotechnologies (NASDAQ:ADVM), Atossa Therapeutics (NASDAQ:ATOS) and Agenus (NASDAQ:AGEN).
The latest price target for Cellectis (NASDAQ: CLLS) was reported by JMP Securities on Wednesday, November 1, 2023. The analyst firm set a price target for 6.00 expecting CLLS to rise to within 12 months (a possible 102.02% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Cellectis (NASDAQ: CLLS) is $2.97 last updated May 9, 2024 at 9:29 AM EDT.
There are no upcoming dividends for Cellectis.
Cellectis’s Q2 earnings are confirmed for Thursday, August 1, 2024.
There is no upcoming split for Cellectis.
Cellectis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.